Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00160615
Status:
COMPLETED
Last Update Posted:
2019-06-10
First Post:
2005-09-08
Brief Title:
Follow-up Study of L059 Levetiracetam in Epileptic Patients With Partial Onset Seizures by Open Label Method
Sponsor:
UCB Japan Co Ltd
Organization:
UCB Pharma
Study Overview
Official Title:
Follow-up Study of L059 Levetiracetam in Epileptic Patients With Partial Onset Seizures by Open Label Method
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The safety and efficacy of L059 was evaluated in patients who completed N165 Clinical Trial of L059 They received L059 at a daily dose from 1000 mg to 3000 mg in addition to their standard concomitant AEDs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None